A new study suggests that people with Alzheimer’s on the drug risperidone, an antipsychotic drug often prescribed as the brand name Risperdal, may be better off continuing to take the drug if they have not experienced negative side effects.
Because of the potential side effects, risperidone is only recommended to be prescribed for three to six months. After that point, a written explanation is required to continue the drug. A study, published in the New England Journal of Medicine and funded by the National Institutes of Health, investigated the effects of discontinuing the medication among individuals who had seen improvements as a result of the drug. Researchers prescribed risperidone to individuals with Alzheimer’s disease who showed signs of agitation and aggression. After 16 weeks, researchers put half of the individuals who did well on the drug on a placebo. The other half continued the treatment. The study found that those on the placebo were twice as likely to have their symptoms return. The rate of side effects and death were equal among the two groups.
Researchers warned that antipsychotics can carry the risk of serious side effects and should not be used on all individuals with Alzheimer’s disease, but discontinuing medication that has achieved benefits is not always the right choice. "One must be cautious about discontinuing the medication,” said study author Dr. D.P. Devanand, director of the division of geriatric psychiatry at Columbia Psychiatry and the New York State Psychiatric Institute in New York City. “If a person does well on it and there are not too many side effects, maybe they should stay on it for a while and be monitored closely."
For more information, read the article: Some With Alzheimer's Better Off Staying on Antipsychotics: Study Or, read the full study: Relapse Risk after Discontinuation of Risperidone in Alzheimer's Disease.
End of Life, Federal Agency Activity, Managed Risk
The nation’s Health and Human Services Department issued new guidance on person-centered planning and self-direction in June and a top official with t...
cheatsheet, Memory Care Best Practices and Research, Memory Care Education, Partnerships, Property Management, Reports
Residents, staff and family help make a senior living community the special place it is, but the design of a building inside and out can be just as im...
The Administration for Community Living, Centers for Disease Control and Prevention, and the National Institute on Aging at the National Institutes of...
Mayor of Boston Martin Walsh announced a new Boston Alzheimer’s initiative, becoming the first large city to join the national Alzheimer’s Workplace A...
Brand Strategy, cheatsheet, Clinical Quality and Quality Care Delivery, Competitive Positioning, Consumer Intelligence, Senior Living Options, Strategy
Assisted living plays a crucial role in the lifecycle of many seniors, providing housing and care at a unique stage of life – but it is only one stage...
California’s 2014-2015 fiscal year budget includes $820,000 of federal funds and legislative authority to implement a three-year Administration on Agi...
End of Life, Facts and Figures, Health and Wellness, Reports
U.S. News and World Report has released its 2014 list of best hospitals across the country, including a look at the top hospitals for geriatric care.
Facts and Figures, Health Care, Memory Care Best Practices and Research, Reports
Smokers are 45% more likely to develop dementia than non-smokers, according to new information published by the World Health Organization in concert w...
End of Life, Facts and Figures, Health and Wellness, Managed Risk, Reports
Approximately 54 million American adults age 50 and older are affected by osteoporosis and low bone mass, according to new data from the National Oste...
Federal Agency Activity, Health and Wellness, Memory Care Best Practices and Research, Memory Care Education
The U.S. Department of Health and Human Services has released a set of materials designed to facilitate conversations with older Americans about brain...